Abstract: Devices and methods can be used to treat long gap esophageal atresia, while obviating much of the delay and complexities associated with current procedures. The devices and methods involve actively stretching the esophagus portions with traction to promote growth of the esophagus portions. Moreover, the devices and methods provided allow for a compression anastomosis to occur between the esophageal ends. This eliminates the need for a second operation to suture the esophageal ends together.

Abstract: This document provides materials and methods related to bacterial compositions containing at least one bacterial organism having tryptophan decarboxylase activity. For example, bacterial compositions containing at least one bacterial organism having tryptophan decarboxylase activity and methods for using such bacterial compositions to improve gastrointestinal epithelial function and/or to treat gastrointestinal disorders are provided.

Abstract: A lactic acid bacterium-containing composition including a lactic acid bacterium having a human papillomavirus (HPV) E7 protein-derived polypeptide on a surface thereof, wherein the HPV E7 protein-derived polypeptide is included in an amount of 0.03 ?g to 1.0 ?g per 1×108 lactic acid bacteria; a therapeutic oral pharmaceutical composition for at least one of an HPV infectious disease and an HPV-associated tumor which includes the lactic acid bacterium-containing composition; and a mucosal immunity-inducing agent which includes the lactic acid bacterium-containing composition.

Abstract: Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37 C and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.

Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.

Abstract: Materials and methods for distinguishing agonistic anti-B7-H1 antibodies from antagonistic anti-B7-H1 antibodies, and for treating subjects diagnosed with clinical conditions such as cancer, pathogenic infection, or autoimmune disease.

Abstract: The present disclosure provide a method and apparatus for pressure-pulse decay performed on whole cylindrical samples whose entire outer surface areas are eligible to receive the pulse. Using the methods and apparatus of the present disclosure, not only is the experimental time dramatically shortened, it also allows for simultaneous determination of local permeabilities parallel and perpendicular to their native bedding planes. Currently, there is no permeability-measurement technique to capable of doing so from a single sample from a single test.

Abstract: A method of making a semi-conducting microfiber. The method includes melting a semi-conducting solid polymer material to form a polymer melt, dipping a tip of a tool into the polymer melt, and lifting the tip of the tool away from the polymer melt, forming a microfiber. A semiconducting microfiber. The semiconducting microfiber contains a non-conjugated semiconducting polymer matrix containing crystalline aggregates with intentionally placed conjugation-break spacers along the polymer backbone. A device containing a plurality of semiconducting microfibers. Each of the semiconducting fibers contains a non-conjugated semiconducting polymer matrix containing crystalline aggregates with intentionally placed conjugation-break spacers along the polymer backbone. An apparatus to make a semiconducting microfiber.

Abstract: Provided is an organic photoelectronic device including a first light-transmitting electrode positioned at a light incidence side, a second light-transmitting electrode facing the first light-transmitting electrode, a photoactive layer positioned between the first light-transmitting electrode and the second light-transmitting electrode and selectively absorbing light in a given (or, alternatively, desired or predetermined) wavelength region, and a selective light transmittance layer positioned between the first light-transmitting electrode and the photoactive layer, between the second light-transmitting electrode and the photoactive layer, or between the first light-transmitting electrode and the photoactive layer and between the second light-transmitting electrode and the photoactive layer and increasing transmittance of the light in a wavelength region other than the given (or, alternatively, desired or predetermined) wavelength region absorbed by the photoactive layer, and an electronic device including th

Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.

Abstract: A method for extracting an elemental metal from agricultural waste including collecting a sample of the waste and performing an electrochemical extraction on the waste to producing a metal precipitate and a byproduct. The method further including collecting the metal precipitate and byproduct produced via the electrochemical extraction for further reaction, recycling, sale, or reuse.

Abstract: Provided is an electrode including conductive particles, which sediment under gravitational force and a liquid fluidizing medium flowing through the electrode, in which the conductive particles are suspended and optionally further including conductive particles, which do not sediment under gravitational force when the fluidizing medium flows in the electrode. Further provided are electrochemical devices and energy storage systems including the electrode.

Abstract: In this work, a hydrophilic, yet slippery solid surface was developed. Because the surfaces are hydrophilic, there is significant affinity between the surface and contacting water, which results in substantial spreading of the contacting liquids on the surface. Due to their strong affinity, a high solid-liquid adhesion having virtually no mobility of the water on the surface occurs. However, counter-intuitively, the disclosed surfaces are highly slippery such that liquids can slide on the surface while maintaining their hydrophilicity. Demonstrated herein are water droplets that can slide on the surface under its own weight, when the hydrophilic, yet slippery solid surface is slightly tilted (?=3°). This indicates that the disclosed hydrophilic surfaces are slippery to water.

Abstract: Processor(s) for detecting malicious software. A hardware virtual machine monitor (HVMM) operates under a host OS. Container(s) initialized with network application template(s) operate under a guest OS VM. A detection module operates under the guest OS VM includes a trigger detection module, a logging module and a container command module. The trigger detection module monitors activity on container(s) for a trigger event. The logging module writes activity report(s) in response to trigger event(s). The container command module issues command(s) in response to trigger event(s). The command(s) include a container start, stop and revert commands. A virtual machine control console operates under the host OS and starts/stops the HVMM. A container control module operates under the guest OSVM and controls container(s) in response to the command(s). The server communication module sends activity report(s) to a central collection network appliance that maintains a repository of activities for infected devices.

Abstract: Provided herein is a soft tissue mimetic formed from a block copolymer hydrogel and methods of making such. The hydrogel comprises a glass formed from a dry blend of polystyrene-poly(ethylene oxide) diblock copolymer (SO) and polystyrene-poly(ethylene oxide)-polystyrene triblock copolymer (SOS) in a molar ratio from between 95:5 and 1:99 SO/SOS and a liquid medium at a concentration between about 32:1 and about 2:1 liquid medium/SO-SOS by weight. The soft tissue mimetic has a fatigue resistance to at least 500,000 compression cycles.

Abstract: The present application discloses a recombinant AAV vector comprising a promoter that targets gene expression to myofibroblast-like lineage of cells in the heart. The present application, also discloses the preparation and use of AAV expression cassettes using a modified periostin promoter that successfully drives gene expression in cardiac myofibroblast-like cells. The present invention encompasses compositions and methods useful for treating myocardial infarction. Further comprising compositions and methods for preparing and using AAV vectors for targeting cells and inducing gene expression. The compositions and methods of the invention are useful for efficiently targeting cardiac myofibroblasts following a cardiac injury, disease, or disorder. Further comprising a kit for effecting alleviation of the various diseases or disorders recited herein.

Abstract: A hybrid composite film, a method of fabricating the hybrid composite film, and an integrated circuit device including the hybrid composite film, the hybrid composite film including a polymer film; and a plurality of organic-inorganic composite particles dispersed in the polymer film, wherein each particle of the plurality of organic-inorganic composite particles includes an inorganic particle and an organic capping layer surrounding the inorganic particle, the organic capping layer having a hydroxyl group-terminated end.

Abstract: Disclosed are materials and methods for treating diseases of the mammalian eye, and in particular, Usher syndrome 1B (USH1B). The invention provides AAV-based, dual-vector systems that facilitate the expression of full-length proteins whose coding sequences exceed that of the polynucleotide packaging capacity of an individual AAV vector. In one embodiment, vector systems are provided that include i) a first AAV vector polynucleotide that includes an inverted terminal repeat at each end of the polynucleotide and a suitable promoter followed by a partial coding sequence that encodes an N-terminal portion of a full-length polypeptide; and ii) a second AAV vector polynucleotide that includes an inverted terminal repeat at each end of the polynucleotide and a partial coding sequence that encodes a C-terminal portion of a full-length polypeptide, optionally followed by a polyadenylation (pA) signal sequence.

Abstract: A method for encoding image signal, according to the present invention, can: encode a partial block coefficient flag indicating whether a coefficient of a current partial block is a non-zero coefficient; encode a first flag indicating whether an absolute value of the coefficient is greater than 1, encode a second flag indicating whether the absolute value of the coefficient is greater than 2; encode the residual coefficients, which have not been encoded, on the basis of the first flag or the second flag in the current partial block; and encode a code for the coefficient of the current partial block.

Abstract: Aspects of the disclosure relate to chimeric antigen receptors (CARs) comprising an antigen binding domain (e.g., anti-TSHR), transmembrane domain (e.g., CD28), and a cytoplasmic domain (e.g., CD27, CD-137, etc.) and a safety mechanism comprising an inducible apoptosis trigger. In some aspects, the disclosure relates to use of the CARs in T cells, compositions, kits and methods for the treatment of thyroid cancers.